ARTICLE

Volume 10,Issue 3

Cite this article
1
Download
18
Citations
72
Views
26 September 2025

Efficacy and Safety Study of Qirui Weishu Capsule in Treating Chronic Gastritis with Abdominal Pain Symptoms

Changqin Luo* Xiaocui Yang1 Yuan Gao1 Guangfu Shen1 Yuanjia Yi1 Yaze Tan1 Lin Xue1 Pan Ning1 Xi Zhang1 Mengjia Gao1
Show Less
1 Department of Gastroenterology, Ankang Central Hospital, Ankang 725000, Shaanxi, China
JMDS 2025 , 10(3), 48–54; https://doi.org/10.18063/JMDS.v10i3.652
© 2025 by the Author. Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC BY-NC 4.0) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Abstract

Objective: To evaluate the efficacy and safety of Qirui Weishu Capsule as monotherapy for chronic gastritis with abdominal pain, providing evidence-based support for clinical application. Methods: A prospective real-world study (January to November 2024) enrolled 60 patients with chronic gastritis and abdominal pain (NRS ≥ 4). Participants received Qirui Weishu Capsule (4 capsules/dose, twice daily before meals). Efficacy was assessed using NRS pain scores, the Gastrointestinal Quality of Life Index (GIQLI), and the Gastrointestinal Symptom Rating Scale (GSRS). Results: Treatment significantly improved gastrointestinal quality of life (GIQLI) and reduced symptom severity (GSRS). Pain/discomfort (NRS) showed sustained relief within 2–4 weeks, with an average pain-relief onset time of 6.67±1.53 days. The pain improvement efficacy rate reached 96% (P < 0.05). Safety: No adverse reactions (e.g., hepatic/kidney impairment, coagulation abnormalities) were observed. Conclusion: Qirui Weishu Capsule rapidly alleviates abdominal pain (within 2–4 weeks), significantly enhances quality of life, and demonstrates favorable safety, making it a preferred treatment for chronic gastritis with abdominal pain.

Keywords
Chronic gastritis
Abdominal pain
Qirui Weishu Capsule
Funding
Ankang Science and Technology Research and Development Planning Project (Project No.: AK2023-SF-12)
References

[1] Correa P, 1992, Human gastric carcinogenesis: a multistep and multifactorial process - First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 52(24): 6735-40.

[2] Parisi I M, Vattiato C, Caramia V, et al., 2024, Chronic Ischemic Gastritis in a Patient With a History of Cancer and Atherosclerotic Disease. ACG Case Rep J. 11(10): e01542.

[3] Han Y P, Min C C, Li Y B, 2023, Diagnosis and treatment of gastric hamartomatous inverted polyp (GHIP) by endoscopic submucosal dissection: A case report. Medicine (Baltimore). 102(13): e33443.

[4] Han S, Chen J, Tian X D, 2022, A randomized, double-blind, multicenter, parallel-group clinical trial of Qirui Weishu Capsule for chronic superficial gastritis with erosion and dampness-heat stagnation syndrome. World Chinese Medicine, 17(10): 1435-1439.

[5] Melo T M, Cunha F L L, Bezerra L M R, 2023, Abdominal and Diaphragmatic Mobility in Adults With Chronic Gastritis: A Cross-Sectional Study. J Chiropr Med. 22(1): 11-19.

[6] Rayamajhi A J, Hamal P K, Bhattarai P R, 2022, Ultrasound Guided Nerve Blocks for Anterior Cutaneous Nerve Entrapment Syndrome, an Overlooked Cause of Chronic Abdominal Pain: A Case Series. J Nepal Health Res Counc. 20(1): 272-275.

[7] Jones A, Veale B, Li T, Aggarwal V R, Twigg J, 2024, Interventions for managing oral submucous fibrosis. Cochrane Database Syst Rev. 2: CD007156.

[8] Yang H C, Qu W, 2025, Diagnostic and therapeutic review of a rare gastric inflammatory fibroid polyps case with distinctive features: A case report. World J Gastrointest Endosc. 17(5): 106074.

[9] Guo F Y, Wang P, Tang X D, 2024, Interpretation of "Expert Consensus on the Diagnosis and Treatment of Chronic Gastritis with Traditional Chinese Medicine (2023)". Chinese Journal of Integrated Traditional and Western Medicine in Digestive Diseases, 32(10): 883-889.

Share
Back to top